neuTEC Competitors

About Genomic Health Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 750,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ® Liquid Select™ test. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn. About Oncotype DX® The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX Breast Recurrence Score®, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score™ predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score™ predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention. With more than 750,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeIQ.com, www.MyBreastCancerTreatment.org or www.MyProstateCancerTreatment.org.

Cellular Solutions has successfully provided in-building wireless coverage to thousands of companies across the United States, including many Fortune 500 companies. Our customer base includes large and small facilities in diverse industries such as commercial offices and warehouses, education, healthcare, hotels and casinos, airports, and governmental agencies. Cellular Solutions provides a turnkey solution to meet your company’s unique needs. Our highly skilled lead technicians will collect all necessary data required by our engineers to design a custom solution to ensure clear cellular coverage throughout any confined space. Our engineering team, having over 30 years of experience in RF in-building design, ensures a flawless wireless repeater solution for any application. Post installation support and maintenance services are provided to ensure satisfaction for the life of the system. Cellular Solutions prides themselves in providing superior customer service and support. Call us today at 989-687-4023 or visit our website at www.cellularsolutions.com

PrecisionMed offers vital products and services facilitating breakthroughs in genetics, drug discovery, biomarker research and molecular diagnostics. We are a leading supplier of high quality, accurately annotated human biological material, and we are the largest private global source of longitudinally collected Human Cerebrospinal Fluid from living normal control as well as diseased populations. Our customers include nearly every major pharmaceutical and biotechnology company, as well as numerous academic and government research institutions. In the United States, we focus on prospective longitudinal collections of blood products and cerebrospinal fluid with associated relevant, detailed clinical data. All of our samples are collected in the United States under U.S. IRB-approved clinical protocols. Collections span most therapeutic and diagnostic areas. Samples and data are procured through PrecisionMed developed networks of research-experienced, specialist physician clinical sites.